Cliff Asness's SRPT Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 6.43 M shares of Sarepta Therapeutics, Inc. (SRPT) worth $138.63 M, representing 0.06% of the portfolio. First purchased in 2012-Q4, this long-term strategic position has been held for 41 quarters.
Based on 13F filings since 2013, Cliff Asness has maintained a long-term strategic position in SRPT, representing a significant commitment to this investment thesis. Largest addition occurred in Q4 2025, adding 6.39 M shares. Largest reduction occurred in Q1 2026, reducing 1.36 M shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Sarepta Therapeutics (SRPT) Holding Value Over Time
Track share changes against reported price movement
Quarterly Sarepta Therapeutics (SRPT) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | -1.36 M | Reduce 17.49% | 6.43 M | $21.55 |
| Q4 2025 | +6.39 M | Add 454.65% | 7.8 M | $21.52 |
| Q3 2025 | +1.28 M | Add 1015.80% | 1.41 M | $18.78 |
| Q2 2025 | +120,594 | Add 2239.44% | 125,979 | $17.10 |
| Q1 2025 | +3,671 | Add 214.18% | 5,385 | $63.82 |
| Q4 2024 | +1,714 | New Buy | 1,714 | $121.59 |
| Q4 2023 | -8,422 | Sold Out | 0 | $0.00 |
| Q3 2023 | -1,299 | Reduce 13.36% | 8,422 | $121.22 |
| Q2 2023 | +1,829 | Add 23.18% | 9,721 | $114.52 |
| Q1 2023 | +5,066 | Add 179.26% | 7,892 | $137.83 |
| Q4 2022 | +95 | Add 3.48% | 2,826 | $129.58 |
| Q3 2022 | +2,731 | New Buy | 2,731 | $110.58 |
| Q1 2021 | -4,834 | Sold Out | 0 | $0.00 |
| Q4 2020 | -180 | Reduce 3.59% | 4,834 | $170.46 |
| Q3 2020 | +3,158 | Add 170.15% | 5,014 | $140.41 |
| Q2 2020 | -2,836 | Reduce 60.44% | 1,856 | $160.56 |
| Q1 2020 | -1,190 | Reduce 20.23% | 4,692 | $97.83 |
| Q4 2019 | -1,754 | Reduce 22.97% | 5,882 | $129.04 |
| Q3 2019 | -8,784 | Reduce 53.50% | 7,636 | $75.30 |
| Q2 2019 | -4,957 | Reduce 23.19% | 16,420 | $151.95 |
| Q1 2019 | +1,196 | Add 5.93% | 21,377 | $119.19 |
| Q4 2018 | -5,437 | Reduce 21.22% | 20,181 | $109.11 |
| Q3 2018 | -45,231 | Reduce 63.84% | 25,618 | $161.53 |
| Q2 2018 | -17,427 | Reduce 19.74% | 70,849 | $132.18 |
| Q1 2018 | +16,176 | Add 22.44% | 88,276 | $74.09 |
| Q4 2017 | -9,368 | Reduce 11.50% | 72,100 | $55.64 |
| Q3 2017 | +28,600 | Add 54.10% | 81,468 | $45.36 |
| Q2 2017 | +501 | Add 0.96% | 52,868 | $33.71 |
| Q1 2017 | +10,648 | Add 25.52% | 52,367 | $29.60 |
| Q4 2016 | +36,738 | Add 737.56% | 41,719 | $27.42 |
| Q3 2016 | +4,981 | New Buy | 4,981 | $61.43 |
| Q2 2016 | -23,268 | Sold Out | 0 | $0.00 |
| Q1 2016 | -8,932 | Reduce 27.74% | 23,268 | $19.51 |
| Q4 2015 | +15,125 | Add 88.58% | 32,200 | $38.57 |
| Q3 2015 | +17,075 | New Buy | 17,075 | $32.09 |
| Q1 2014 | -32,000 | Sold Out | 0 | $0.00 |
| Q4 2013 | -14,488 | Reduce 31.17% | 32,000 | $20.38 |
| Q3 2013 | +16,115 | Add 53.06% | 46,488 | $47.24 |
| Q2 2013 | +30,373 | Add 0.00% | 30,373 | $38.06 |
| Q4 2012 | +34,647 | Add 0.00% | 34,647 | $25.80 |
Cliff Asness's Sarepta Therapeutics Investment FAQs
Cliff Asness first purchased Sarepta Therapeutics, Inc. (SRPT) in Q4 2012, acquiring 34,647 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Sarepta Therapeutics, Inc. (SRPT) for 41 quarters since Q4 2012.
Cliff Asness's largest addition to Sarepta Therapeutics, Inc. (SRPT) was in Q4 2025, adding 7,796,535 shares worth $167.78 M.
According to the latest 13F filing for Q1 2026, Cliff Asness's firm, Aqr Capital Management LLC, owns 6,433,112 shares of Sarepta Therapeutics, Inc. (SRPT), valued at approximately $138.63 M.
As of the Q1 2026 filing, Sarepta Therapeutics, Inc. (SRPT) represents approximately 0.06% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in Sarepta Therapeutics, Inc. (SRPT) was 7,796,535 shares, as reported at the end of Q4 2025.